Showing results (141-150 of 315) with videos related to

Sort By:
Pageof 32
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 16, 2003
Role of gastrointestinal hormones in postprandial reduction of bone resorptionDennis B Henriksen, Peter Alexandersen, Nina H Bjarnason, et al.
Bone|October 18, 2019
GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2Lærke S Gasbjerg, Bolette Hartmann, Mikkel B Christensen, et al.
Pediatric Blood & Cancer|July 2, 2024
Bone remodeling in survivors of pediatric hematopoietic stem cell transplantation: Impact of heavy resistance trainingLise Marie Krogh, Anne Nissen, Sarah Weischendorff, et al.
International Journal of Obesity (2005)|December 13, 2018
Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profilesSofia S Pereira, Marta Guimarães, Rui Almeida, et al.
British Journal of Pharmacology|June 16, 2022
Glucose-dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet-fed miceGeke Aline Boer, Jenna Elizabeth Hunt, Maria Buur Nordskov Gabe, et al.
British Journal of Pharmacology|January 22, 2023
Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in miceMaria Buur Nordskov Gabe, Liv von Voss, Jenna Elizabeth Hunt, et al.
Diabetes|July 2, 2017
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP ReceptorMeena Asmar, Ali Asmar, Lene Simonsen, et al.
Molecular Metabolism|January 13, 2022
Comparative analysis of oral and intraperitoneal glucose tolerance tests in miceLewin Small, Amy Ehrlich, Jo Iversen, et al.
Diabetes, Obesity & Metabolism|April 15, 2018
Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?Emilie S Andersen, Asger Lund, Jonatan I Bagger, et al.
The Journal of Clinical Endocrinology and Metabolism|September 14, 2020
The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 ReceptorAli Asmar, Per K Cramon, Meena Asmar, et al.
Pageof 32